Pieris Pharmaceuticals, Inc. (PIRS): Price and Financial Metrics

Pieris Pharmaceuticals, Inc. (PIRS)

Today's Latest Price: $3.48 USD

0.12 (-3.33%)

Updated Jun 1 6:55pm

Add PIRS to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 336 in Biotech

See all "A" rated Strong Buy stocks

PIRS Stock Summary

  • Of note is the ratio of Pieris Pharmaceuticals Inc's sales and general administrative expense to its total operating expenses; just 12.97% of US stocks have a lower such ratio.
  • The ratio of debt to operating expenses for Pieris Pharmaceuticals Inc is higher than it is for about merely 18.88% of US stocks.
  • Revenue growth over the past 12 months for Pieris Pharmaceuticals Inc comes in at 52.25%, a number that bests 90.02% of the US stocks we're tracking.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Pieris Pharmaceuticals Inc are CDTX, MGEN, WVE, SYBX, and UMRX.
  • Visit PIRS's SEC page to see the company's official filings. To visit the company's web site, go to www.pieris.com.
PIRS Daily Price Range
PIRS 52-Week Price Range

PIRS Stock Price Chart More Charts

PIRS Price/Volume Stats

Current price $3.48 52-week high $6.04
Prev. close $3.60 52-week low $1.60
Day low $3.30 Volume 573,900
Day high $3.59 Avg. volume 474,977
50-day MA $2.67 Dividend yield N/A
200-day MA $3.44 Market Cap 182.08M

Pieris Pharmaceuticals, Inc. (PIRS) Company Bio

Pieris Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, discovers and develops Anticalin-based drugs. The company develops Anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in blood plasma and other bodily fluids. The company is based in Boston, Massachusetts.

PIRS Latest News Stream

Event/TimeNews Detail
Loading, please wait...

PIRS Latest Social Stream

Loading social stream, please wait...

View Full PIRS Social Stream

Latest PIRS News From Around the Web

Below are the latest news stories about Pieris Pharmaceuticals Inc that investors may wish to consider to help them evaluate PIRS as an investment opportunity.

Pieris Pharmaceuticals to Present at the Jefferies 2020 Virtual Healthcare Conference

BOSTON, MA / ACCESSWIRE / May 28, 2020 / Pieris Pharmaceuticals, Inc. (PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer, and other indications, announced today that management will present at the Jefferies 2020 Virtual Healthcare Conference on Thursday, June 4, 2020 at 3:30 PM EDT. Pieris is a clinical-stage biotechnology company that discovers and develops Anticalin protein-based drugs to target validated disease pathways in a unique and transformative way. This press release contains forward-looking statements as that term is defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.

Yahoo | May 28, 2020

Edited Transcript of PIRS earnings conference call or presentation 11-May-20 12:00pm GMT

Q1 2020 Pieris Pharmaceuticals Inc Earnings Call

Yahoo | May 28, 2020

Earnings Update: Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Just Reported And Analysts Are Boosting Their Estimates

Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) just released its latest first-quarter results and things are looking...

Yahoo | May 14, 2020

Pieris Pharmaceuticals (PIRS) Reports Q1 Loss, Tops Revenue Estimates

Pieris Pharmaceuticals (PIRS) delivered earnings and revenue surprises of 56.25% and 40.58%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | May 11, 2020

Pieris Pharmaceuticals: Q1 Earnings Insights

Shares of Pieris Pharmaceuticals (NASDAQ:PIRS) remained unaffected at $2.91 after the company reported Q1 results.Quarterly Results Earnings per share rose 65.00% year over year to ($0.07), which beat the estimate of ($0.17).Revenue of $13,261,000 up by 55.19% year over year, which beat the estimate of $8,840,000.Guidance Earnings guidance hasn't been issued by the company for now.View more earnings on PIRSPieris Pharmaceuticals hasn't issued any revenue guidance for the time being.Recent Stock Performance Company's 52-week high was at $6.04Company's 52-week low was at $1.60Price action over last quarter: Up 34.72%Company Profile Pieris Pharmaceuticals Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of Anticalin class of biotherapeutics....

Yahoo | May 11, 2020

Read More 'PIRS' Stories Here

PIRS Price Returns

1-mo 48.72%
3-mo 3.88%
6-mo 1.46%
1-year -17.34%
3-year -28.83%
5-year 17.17%
YTD -3.87%
2019 36.09%
2018 -64.77%
2017 435.46%
2016 -38.43%
2015 N/A

Continue Researching PIRS

Want to see what other sources are saying about Pieris Pharmaceuticals Inc's financials and stock price? Try the links below:

Pieris Pharmaceuticals Inc (PIRS) Stock Price | Nasdaq
Pieris Pharmaceuticals Inc (PIRS) Stock Quote, History and News - Yahoo Finance
Pieris Pharmaceuticals Inc (PIRS) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.9622 seconds.